Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients. A Report From the National Heart, Lung, and Blood Institute Dynamic Registry

JACC: Cardiovascular Interventions

Volumn 1, Issue 2, 2008, Pages 139-147

  Mulukutla, Suresh R ^a   Vlachos, Helen A ^a   Marroquin, Oscar C ^a   Selzer, Faith ^a   Holper, Elizabeth M ^b   Abbott, J Dawn ^c   Laskey, Warren K ^d   Williams, David O ^c   Smith, Conrad ^a   Anderson, William D ^a   Lee, Joon S ^a   Srinivas, Vankeepuram ^e   Kelsey, Sheryl F ^a   Kip, Kevin E ^f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; INSULIN; ORAL ANTIDIABETIC AGENT; PACLITAXEL; RAPAMYCIN;

ADULT; ARTICLE; BARE METAL STENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC DIET; DIABETIC PATIENT; DISEASE REGISTRY; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STENT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG-ELUTING STENTS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KAPLAN-MEIERS ESTIMATE; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; STENTS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 41949096130     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.02.005     Document Type: Article

References (31)

1. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
2. Stein B., Weintraub W.S., Gebhart S.P., et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91 (1995) 979-989
3. Gurm H.S., Sarembock I.J., Kereiakes D.J., et al. Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking Angiomax to reduced clinical events (REPLACE)-2 Trial. J Am Coll Cardiol 45 (2005) 1932-1938
4. Urban P., Gershlick A., Guagliumi G., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113 (2006) 1434-1441
5. Sabate M., Jimenez-Quevedo P., Angiolillo D., et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
6. BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 96 (1997) 1761-1769
7. Rozenman Y., Sapoznikov D., and Gotsman M. Restenosis and progression of coronary disease after balloon angioplasty in patients with diabetes mellitus. Clin Cardiol 23 (2000) 890-894
8. Carson J.L., Scholz P.M., Chen A.Y., et al. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol 40 (2002) 418-423
9. Verghese M., Frye R.L., Lennon R., Barsness G.W., and Holmes Jr. D.R. Comparison of survival after successful percutaneous coronary intervention of patients with diabetes mellitus receiving insulin versus those receiving only diet and/or oral hypoglycemic agents. Am J Cardiol 93 (2004) 399-403
10. Abizaid A., Kornowski R., Mintz G.S., et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 32 (1998) 584-589
11. Hermiller J.B., Raizner A., Cannon L., et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS IV trial. J Am Coll Cardiol 45 (2005) 117-119
12. Moussa I., Leon M.B., Baim D., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS substudy. Circulation 109 (2004) 2273-2278
13. Pfisterer M., Brunner-La Rocca H.B., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
14. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
15. Machecourt J., Danchin N., Lablanche J.M., et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT matched-cohort registry. J Am Coll Cardiol 50 (2007) 501-508
16. Williams D.O., Holubkov R., Yeh W., et al. Percutaneous coronary intervention in the current era compared with 1985-86; the National Heart Lung and Blood Institute Registries. Circulation 102 (2000) 2945-2951
17. Laskey W.K., Williams D.O., Vlachos H.A., et al. Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the National Heart Lung, and Blood Institute Dynamic Registry. Am J Cardiol 87 (2001) 964-969
18. Macaya C., Garcia-Garcia H.M., Colombo A., et al. One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease. Sirolimus stent vs. coronary artery bypass surgery and bare metal stent: insights from ARTS II and ARTS I. Euro Interv 2 (2006) 69-76
19. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients. Circulation 109 (2004) 2273
20. Simonton CA, Brodie B, Cheek C, et al. Comparative late clinical outcomes of paclitaxel and sirolimus-eluting coronary stents in diabetic patients from a large prospective multicenter registry: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. Presented at: Innovation in Intervention: i2 Summit 2006; March 11-14, 2006: Atlanta, GA.
21. Patterson C., Mapera S., Li H.H., et al. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol 26 (2006) 1473-1480
22. Laskey W.K., Yancy C.W., and Maisel W.H. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006. Circulation 115 (2007) 2352-2357
23. Marroquin O.C., Selzer F., Mulukutla S.R., et al. A comparison of bare metal and drug-eluting stents for off-label indications: findings from the NHLBI Dynamic Registry. N Engl J Med 358 (2008) 342-352
24. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
25. Sobel B.E. Acceleration of restenosis by diabetes: pathogenetic implications. Circulation 103 (2001) 1185-1187
26. Donahoe S.M., Stewart G.C., McCabe C.H., et al. Diabetes and mortality following acute coronary syndromes. JAMA 298 (2007) 765-775
27. Antoniucci D., Valenti R., Migliorini A., et al. Impact of insulin-requiring diabetes mellitus on effectiveness of reperfusion and outcome of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 93 (2004) 1170-1172
28. Detre K.M., Guo P., Holubkov R., et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 99 (1999) 633-640
29. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
30. Iaokovu I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
31. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678